UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Amendment No.1)
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of
earliest event reported): November 2, 2021 (
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of | (Commission File Number) | (IRS Employer Identification No.) | ||
incorporation) |
(Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Explanatory Note
Item 5.02 Election of Directors; Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As reported in the Original Filing, on September 27, 2021, the Company’s Board of Directors appointed Michael Moran as the Company’s Executive Vice President, Chief Commercial Officer, effective immediately, in which position he will serve as the Company’s principal operating officer. The Board had not approved any material compensatory arrangement for Mr. Moran as of the date of the Original Filing. The Company is filing this Amendment Filing to disclose the compensation of Mr. Moran in his new role. No other changes have been made to the Original Filing.
On November 2, 2021, in connection with his new role, the Compensation Committee of the Board approved an annual base salary for Mr. Moran of $455,800 effective as of October 1, 2021 and a target annual bonus for fiscal year 2021 set at 70% of his base salary, pro-rated from October 1, 2021 in accordance with the terms of the Company’s performance bonus program for the 2021 calendar year, with the amount of such bonus to be determined by the Compensation Committee based on the Company’s achievement of its annual corporate objectives established by the Compensation Committee.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: November 8, 2021 | EAGLE PHARMACEUTICALS, INC. | |
By: | /s/ Scott Tarriff | |
Scott Tarriff | ||
Chief Executive Officer |
Cover |
Sep. 27, 2021 |
---|---|
Cover [Abstract] | |
Document Type | 8-K/A |
Amendment Flag | true |
Amendment Description | In accordance with Instruction No. 2 to Item 5.02 of Form 8-K, Eagle Pharmaceuticals, Inc., or the Company, is filing this Current Report on Form 8-K/A, or the Amendment Filing, to amend the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on October 1, 2021, or the Original Filing. Except as expressly set forth herein, this Amendment Filing does not amend, modify or update the disclosures contained in the Original Filing. |
Document Period End Date | Sep. 27, 2021 |
Entity File Number | 001-36306 |
Entity Registrant Name | Eagle Pharmaceuticals, Inc. |
Entity Central Index Key | 0000827871 |
Entity Tax Identification Number | 20-8179278 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 50 Tice Boulevard |
Entity Address, Address Line Two | Suite 315 |
Entity Address, City or Town | Woodcliff Lake |
Entity Address, State or Province | NJ |
Entity Address, Postal Zip Code | 07677 |
City Area Code | 201 |
Local Phone Number | 326-5300 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock (par value $0.001 per share) |
Trading Symbol | EGRX |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
RHY_U=3_ 102P,$% @ $X!H4Y>*NQS $P( L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/: (7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU M1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'B4?'D78FYJD6:>IK&HP=MX1PT$ MG53$WHI"/J:Q8;!EK '$NW2:9;/46PQFN1BUMIS> A(H!"DHV1%[A$O\G7 D(GP&LK\,S4-AB.G8RF M2&]B]#V,YU#BG/]3(U45%K"FHO409.B1P74&0ZRQB28)UD-N5G0&[O+H YMR MR"9JZJ8IGJ,.>%,.]D9/)508H'Q3F:B\]E-L.>F.7F=Z_S!YU!Y:YU;*O8=7 MLN48Y0]02P,$% @ $X!H4R0>FZ*M ^ $ !H !X;"]?
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end
)C8.ZB87
MYC&27^ %>UL#&\?^(]=0G-]()""LJ2-/=+/^&[&_G4)K#S\/'CRVFG@A(I7$
MTHUKS=EVI;+,/"^)OE8ZOE:B]A/-[&=D;Q"TR,#(Q,#DR-U]L86(N>&ULS9U=;^.X%8;O"_0_
ML-Z;%AC'<8(MD.S,+C*>9&%L-DECSVS;1;&@)<810I,!)2?VOR\IB;)$\4A*
MBI+,148COH=Z*3XAJ0]2'W_:;2AZ(2)-./LTFAX=CQ!A$8\3MOXT^KH87RQF
M\_D(I1EF,::K(H$V\IF$[G" C:HF6@K@@ "M&72A) EQ!-(H'D IY8^1*@@D[UH%8'^"5N0:"O[S?WT9+5,,FJ[#&U+G/52
M@+FJCS+2@R $,&42D: